Urteste S.A. Logo

Urteste S.A.

Develops non-invasive urine tests for the early detection of multiple cancers.

URT | WAR

Overview

Corporate Details

ISIN(s):
PLURTST00010 (+1 more)
LEI:
259400Q4S6JIKFQHGU06
Country:
Poland
Address:
Gdańsk Starodworska 1, 80-137 Gdańsk

Description

Urteste S.A. is a biotechnology company specializing in the development of non-invasive diagnostic technologies for early cancer detection. The company's core focus is on creating a method to detect multiple types of cancer from a single urine sample. This approach aims to identify malignancies at their earliest stages, potentially improving patient survival rates. The development pipeline includes diagnostic tests for various cancers, with projects such as a prototype for detecting brain tumors and planned clinical trials for a pancreatic cancer test.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-12 11:38
Zawarcie umów objęcia akcji serii G - Content (PL)
Polish 1.8 KB
2025-12-10 10:57
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym…
Polish 1.6 KB
2025-12-04 17:00
Podjęte uchwały
Polish 294.0 KB
2025-12-04 17:00
Treść uchwał podjętych podczas obrad Nadzwyczajnego Walnego Zgromadzenia w dniu…
Polish 657 bytes
2025-11-28 08:18
Raport kwartalny 3Q2025
Polish 1.2 MB
2025-11-07 16:00
OPINIA ZARZĄDU uzasadniająca powody pozbawienia akcjonariuszy prawa poboru akcji
Polish 178.5 KB
2025-11-07 16:00
Projekty uchwał
Polish 229.9 KB
2025-11-07 16:00
Pełnomocnictwo udzielane przez osoby prawne do uczestnictwa
Polish 160.7 KB
2025-11-07 16:00
Pełnomocnictwo udzielane przez osoby fizyczne do uczestnictwa
Polish 156.4 KB
2025-11-07 16:00
INFORMACJE DOTYCZĄCE PRZETWARZANIA DANYCH OSOBOWYCH AKCJONARIUSZY I PEŁNOMOCNIK…
Polish 191.5 KB
2025-11-07 16:00
INFORMACJA o ogólnej liczbie akcji w Spółce Urteste S.A.
Polish 118.9 KB
2025-11-07 16:00
FORMULARZ pozwalający na wykonywanie prawa głosu przez pełnomocnika
Polish 284.9 KB
2025-11-07 16:00
Ogłoszenie Zarządu Urteste S.A.
Polish 217.3 KB
2025-11-07 16:00
Zwołanie Nadzwyczajnego Walnego Zgromadzenia na dzień 4 grudnia 2025 roku - Con…
Polish 1.5 KB
2025-11-07 10:36
Zawarcie dwóch umów inwestycyjnych dotyczących dokapitalizowania Spółki - Conte…
Polish 2.6 KB

Automate Your Workflow. Get a real-time feed of all Urteste S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Urteste S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Urteste S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Isofol Medical Logo
Clinical-stage biotech developing a folate-based therapy to enhance cancer treatments.
Sweden
ISOFOL
IVIM Technology, Inc. Logo
Provides intravital microscopy systems and CRO services for biomedical research.
South Korea
460470
IXICO PLC Logo
Provides AI-driven neuroimaging and data analytics for neuroscience clinical trials.
United Kingdom
IXI
Jade Biosciences, Inc. Logo
A clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.
United States of America
JBIO
Jasper Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies targeting mast and hematopoietic stem cells.
United States of America
JSPR
J. Molner AS Logo
A CDRO developing generic sterile injectable and dermatological dosage forms.
Estonia
JML
Kadimastem Ltd. Logo
Clinical-stage cell therapy company developing treatments for ALS and diabetes.
Israel
KDST
KAINOS MEDICINE, INC. Logo
Develops small molecule therapeutics for neurodegenerative, infectious, and oncological diseases.
South Korea
284620
Kairos Pharma, LTD. Logo
Develops oncology therapies targeting drug resistance and immune suppression.
United States of America
KAPA
Kancera Logo
Pharmaceutical company seeking a reverse takeover to leverage its public listing.
Sweden
KAN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.